Zymeworks Inc. has halted the development of its cancer drug ZW171, leading to a decline in its stock price and sparking concerns about the company’s future pipeline and revenue streams.

Zymeworks Inc., a clinical-stage biotech company, navigates market fluctuations and challenges in the biotech sector while remaining committed to innovation and partnerships in its mission to develop multifunctional biotherapeutics for cancer treatm…

Zymeworks Inc is expanding its pipeline despite modest revenue growth, but its financials paint a mixed picture, contrasting with BeiGene’s strong sales and profitability.